PRESS RELEASE:
The World’s First Drug-Eluting Coronary Stent-on-a-Wire Integrated Delivery System Downsizes Catheters, Facilitates Transradial Intevention (TRI) and Maximizes Procedural Efficiency
NEW PROVIDENCE, N.J.–(BUSINESS WIRE)–December 15, 2015–
Svelte Medical Systems, Inc. today announced it received CE Mark certification of the SLENDER Sirolimus-Eluting Coronary Stent-On-A-Wire Integrated Delivery System (IDS) for the treatment of coronary artery disease. The first advance in stent delivery since the rapid-exchange catheter, SLENDER IDS is the world’s lowest profile drug-eluting stent (DES), reducing the catheter size necessary to perform percutaneous coronary intervention (PCI) and facilitating transradial intervention (TRI) in more patients. Incorporating Asahi guide wire technology, a specialized balloon design and a new class of bioresorbable drug carrier from DSM Biomedical, SLENDER IDS is designed to enhance direct stenting, enabling interventional cardiologists to extracts steps, time and cost from stenting procedures.
“SLENDER IDS is an entirely new approach to coronary stenting, offering unique clinical and procedural benefits which we look forward to integrating into our practice,” said Stefan Verheye, MD, PhD, principal investigator of the DIRECT II study supporting CE Mark certification and Co-Director of the Antwerp Cardiovascular Institute at the Middelheim Hospital in Antwerp, Belgium. “No reports of stent thrombosis dating back nearly 4 years to the first-in-man study are reassuring signals relating to safety, and product efficacy appears as good as any current generation DES. The unique attributes of this product help us in our ongoing efforts to optimize patient care.”
SLENDER IDS combines the latest guide wire, delivery balloon and DES technologies into a single ‘all-in-one’ fixed-wire system. Asahi ACT ONE™ wire technology provides precise steering while proprietary Balloon Control Band (BCB™) technology allows controlled balloon growth to safely perform direct stenting and high-pressure post-dilatation(s). DISCREET™ drug coating, applied to a highly conformable cobalt chrome stent, is composed of the well-studied drug sirolimus and a natural, amino acid-based polyesteramide (PEA) bioresorbable drug carrier proprietary to DSM Biomedical, a global leader in biomaterials science and regenerative medicine. In the DIRECT I and II clinical studies, exceptionally low TLR was observed while no deaths or stent thromboses were reported beyond 3 years.
“Adding value in the modern healthcare environment requires new technologies to improve efficiency and reduce cost while enhancing patient outcomes and comfort. SLENDER IDS is a highly differentiated platform delivering value to all constituents involved in coronary stenting – patients, physicians, providers and payers,” said Jack Darby, President and CEO of Svelte Medical Systems, Inc. “We are extremely pleased to achieve the CE Mark for SLENDER IDS and look forward to introducing it in cath labs in Europe.”
Svelte plans to commercialize SLENDER IDS in select accounts in Europe and commence an IDE study in support of PMA approval in 2016. A rapid-exchange DES system with proprietary technology designed to facilitate direct stenting will also be commercialized in Europe in 2016.
About Svelte Medical Systems
Headquartered in New Providence, New Jersey, Svelte Medical Systems (www.sveltemedical.com) is a privately-held company engaged in the development of highly deliverable balloon expandable stents. Statements made in this press release that look forward in time or that express beliefs, expectations or hopes regarding future occurrences or anticipated outcomes or benefits, are forward-looking statements. A number of risks and uncertainties, such as risks associated with product development and commercialization efforts, results of clinical trials, ultimate clinical outcomes and benefit of the company’s products to patients, market and physician acceptance of the products, intellectual property protection and competitive product offerings, could cause actual events to adversely differ from the expectations indicated in these forward looking statements.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151215005559/en/
Svelte Medical Systems, Inc.
Jack Darby, 908-264-2012
President and CEO
jdarby@sveltemedical.com